MedTrace Logo

Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis

NCT00559130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-06-07

No results posted yet for this study

Summary

The hypothesis of this study is use of CytoSorb hemoperfusion device as an adjunctive therapy to the standard of care in treating ARDS/ALI patients in the setting of sepsis will result in improved clearance of cytokines when compared to control patients receiving only the standard of care.

Conditions

  • Acute Respiratory Distress Syndrome
  • Acute Lung Injury
  • Sepsis

Interventions

DEVICE

CytoSorb Hemoperfusion

Daily hemoperfusion for 6 hours with CytoSorb device

Sponsors & Collaborators

  • MedaSorb Technologies, Inc

    lead INDUSTRY

Principal Investigators

  • Martin K Kuhlmann, Prof. Dr. · Vivantes Klinikum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559130 on ClinicalTrials.gov